Universal Ibogaine Inc · TSXV:IBO
Universal Ibogaine — Investor Presentation (September 2021)
30 slides from Universal Ibogaine's investor presentation, September 2021
Slide 1: Universal Ibogaine
TSX-V: IBO UNIVERSAL IBOGAINE 1 TSX-V: IBO
Slide 2: Disclaimer and Use of Forward-Looking Statements
. (l DISCLAIMER AND USE OF FORWARD-LOOKING STATEMENTS TSX-V: IBO ( This presentation is provided for information purposes only and shall not constitute an offer to buy, sell, issue or subscribe for, or the solicitation of an offer to buy, sell or issue, or subscribe for any securities. It has been p
Slide 3: Universal Ibogaine Mission
TSX-V: IBO UNIVERSAL IBOGAINE MISSION We aim to provide those living with addiction with an improved treatment toward better outcomes by developing and applying a state-of-the-art, comprehensive and holistic, care model, while introducing ibogaine as a central piece of the solution set. 3 TSX-V: IBO
Slide 4: Investment Thesis
TSX-V: IBO INVESTMENT THESIS 1. Universal Ibogaine offers an opportunity to help tackle the scourge of addiction. We present an ethical, medically-supervised and regulatory- sanctioned channel to participate in the PSYCHEDELICS space. 2. Our ibogaine “biotech” play is inherently “de-risked” due to t
Slide 5: Our Founding Story
TSX-V: IBO OUR FOUNDING STORY MEETING Universal Ibogaine was born in 2018: Canadian financier Shayne Nyquvest met Dr. Alberto Sola, the world's most experienced ibogaine treatment provider, at his clinic in Cancun (Mexico). CLEAR SKY Dr. Sola's ibogaine treatment protocol has disrupted addiction by
Slide 6: Progress to Date
TSX-V: IBO PROGRESS TO DATE • Public listing on the TSX Venture Exchange in September 2021* through amalgamation with P Squared Renewables – A Capital Pool Company • Raised $6M to support ibogaine clinical development and addiction clinics rollout • Arranging for clinical trials to medicalize ibogai
Slide 7: Our Leadership Team
TSX-V: IBO OUR LEADERSHIP TEAM Dr. Rami Batal, PharmD/PhD – Chief Executive Officer Dr. Rami Batal is a seasoned biopharmaceutical industry executive and a healthcare professional who has a passion for, and expertise and experience in, neuropsychiatry and mental health/behavioral health illnesses, i
Slide 8: Executive (Operating) Board of Directors
TSX-V: IBO EXECUTIVE (OPERATING) BOARD OF DIRECTORS Chief Ian Campbell, MBA – Chairman (Independent) Chief Ian Campbell (Xalek) is a hereditary chief of the Squamish Nation located in Vancouver, British Columbia. He has served as an elected member of council since 2005, and was appointed as a Politi
Slide 9: Executive (Operating) Board of Directors
TSX-V: IBO EXECUTIVE (OPERATING) BOARD OF DIRECTORS Robert Turner, ICD.D, MBA – Director (Independent) Mr. Turner is President of his own incorporated consulting firm and a Principal within Western Management Consultants. His consulting focus is providing guidance to boards on their governance inclu
Slide 10: Planned Team Expansion
TSX-V: IBO PLANNED TEAM EXPANSION 2021 • Chief Medical Officer; Chief Clinics Officer; Vice-President Drug Development • Board Members: o Capital Markets; Finance/Audit (CPA) 2022 • Medical and Scientific Advisory Board • Business Advisory Board 10 TSX-V: IBO
Slide 11: Addiction and Ibogaine
TSX-V: IBO ADDICTION AND IBOGAINE 11 TSX-V: IBO
Slide 12: Addiction Figures and Facts
TSX-V: IBO ADDICTION FIGURES AND FACTS • On average every 2 hours, a death occurs in Canada due to illicit drug overdose*. • Addiction is closely intertwined with mental/behavioral health and CNS – All subject to an increasing societal and industrial focus. • Current addiction management, although a
Slide 13: Ibogaine: A Medical Psychedelic for Addiction
TSX-V: IBO IBOGAINE: A MEDICAL PSYCHEDELIC FOR ADDICTION • Ibogaine is a naturally-occurring molecule derived from the root bark of the iboga tree and other plants. • Potent and serious medical psychedelic which evidence demonstrates has addiction-interrupting properties • Broad spectrum (promiscuou
Slide 14: The Plan
TSX-V: IBO THE PLAN 14 TSX-V: IBO
Slide 15: To Transform Addiction Management, While Developing Ibogaine
TSX-V: IBO TO TRANSFORM ADDICTION MANAGEMENT, WHILE DEVELOPING IBOGAINE AS A CENTRAL COMPONENT OF INNOVATIVE ADDICTION TREATMENT 1 2 Addiction Drug (Ibogaine) Addiction Clinics Development Caribbean-Based Indigenous Addiction Holistic Addiction Management* Management* 4 3 *Introduction of ibogaine a
Slide 16: Drug (Ibogaine) Development Program: Impetus
TSX-V: IBO 1 DRUG (IBOGAINE) DEVELPOMENT PROGRAM: IMPETUS • We are pursuing a Health Canada approval to conduct a clinical trial to demonstrate the safety and efficacy of ibogaine in treating opioid use disorder. • The study is intended to ultimately lead to the medical use of ibogaine in Canada, an
Slide 17: Drug Development Program: Clear Sky Treatment Protocol
TSX-V: IBO DRUG (IBOGAINE) DEVELPOMENT PROGRAM: CLEAR SKY 1 TREATMENT PROTOCOL • Universal Ibogaine has acquired treatment/safety protocol (worldwide) rights from Clear Sky Recovery in Cancun (Mexico), along with patient safety data and the Clear Sky Recovery Solution brand. • The Clear Sky treatmen
Slide 18: Drug Development Program: Projected Roadmap
TSX-V: IBO 1 DRUG (IBOGAINE) DEVELOPMENT PROGRAM: PROJECTED ROADMAP * *Human proof of concept study [usually aligned with a ph2B (phase 2) development stage] 18 TSX-V: IBO
Slide 19: Drug Development Program: Advancement Scenarios
TSX-V: IBO 1 DRUG (IBOGAINE) DEVELOPMENT PROGRAM: ADVANCEMENT SCENARIOS Focused Medicalization / Commercialization Special Access** CTA to NOL* Ph2/HPOC Ph3 / Pivotal Program to NOC* Full Medicalization / Commercialization *Acronyms: NOL = No Objection Letter (from Health Canada); NOC = Notice of Co
Slide 20: Addiction Clinics: First Step Kelburn
TSX-V: IBO 2 ADDICTION CLINCS: FIRST STEP KELBURN • Kelburn (greater Winnipeg, MB) rehab center acquired, along with 50 acres • Kelburn is revenue generating with substantial growth opportunities: o Development of detox center o Introduction of “novo treatments”, including psychedelics as authorized
Slide 21: Addiction Clinics Milestones
TSX-V: IBO 2 ADDICTION CLINICS MILESTONES --2021-- --2022--- Q4 Q1 Q2 Q3 Q4 (Onward) Kelburn Optimized Clinic acquisition targets identified “Corporate” Clinic 2 Acquired “Corporate” Clinics 3+ Acquired (Canada / US) Addiction Management Model Finalized Certified Training / Managed Franchising Rollo
Slide 22: Exploratory Interests in Support of the Plan
TSX-V: IBO EXPLORATORY INTERESTS IN SUPPORT OF THE PLAN 3 Indigenous Community Engagement • Collaboration opportunities related to indigenous holistic medicine, particularly the utility of medical psychedelics / ibogaine, as well as outpatient / in- community care and aftercare • Exploration of lega
Slide 23: Key, Near-Term, Milestones
TSX-V: IBO KEY, NEAR-TERM, MILESTONES Clinic 3+; Ph2 / HPOC Licensing / Start + Franchising * CTA / NOL Caribbean Clinic Indigenous Health MOU* Pre-CTA* Meeting *Acronyms: CTA = clinical trial application; MOU = Memorandum of Understanding 23 TSX-V: IBO
Slide 24: Financial Considerations
TSX-V: IBO FINANCIAL CONSIDERATIONS 24 TSX-V: IBO
Slide 25: Revenue and Valuation Potential
TSX-V: IBO REVENUE AND VALUATION POTENTIAL • POTENTIAL REVENUE SOURCES: i) clinics (direct operation = “corporate clinics”; certified training/licensing/franchising); ii) patient referral or direct operation in the Caribbean where and when authorized; iii) operation on indigenous lands where and whe
Slide 26: Comparable Valuations
TSX-V: IBO COMPARABLE VALUATIONS* Company Valuations Universal Ibogaine Numinus FieldTrip MindMed Compass ATAI $45M $175M $390M $1.23B $1.40B $2.72B *Source: http://ca.finance.yahoo.com/ (early September 2021 readout) 26 TSX-V: IBO
Slide 27: Use of Raised Proceeds
TSX-V: IBO USE OF RAISED PROCEEDS 27 TSX-V: IBO
Slide 28: Capital Structure (Post Raise)
TSX-V: IBO CAPITAL STRUCTURE (POST RAISE) 28 TSX-V: IBO
Slide 29: Capital Structure (Post Raise): Reserved for Issue
TSX-V: IBO CAPITAL STRUCTURE (POST RAISE): RESERVED FOR ISSUE 29 TSX-V: IBO
Slide 30: Freedom From Addiction Is Possible
Freedom From Addiction Is Possible www.UniversalIbogaine.com TSX-V: IBO Rami.Batal@UniversalIbogaine.com September 2021
Universal Ibogaine — Investor Presentation (September 2021) on 6ix